Phase II Trial of RAD001 in Refractory Colorectal Cancer

Swedish Medical Center22 enrolled

Overview

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Study is completed and closed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

RAD001DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens * Measurable disease * ECOG 0-2 Exclusion Criteria: * CNS disease * Chemotherapy or radiotherapy \< 4 weeks prior * Active bleeding diathesis

Locations (1)

Swedish Cancer Institute

Seattle, Washington, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.